This round of financing is led by Qiming venture capital and followed by the old shareholder Danlu capital. The financing funds will be used for team expansion, product R & D, clinical project registration and market development, so as to further consolidate the company's medical science and technology strength.

Beijing Zhiyuan huitu Technology Co., Ltd. (Vistel, hereinafter referred to as "Zhiyuan huitu") was founded in 2016 by former Intel executive sun Yuhui and researcher Ding Dayong. It is committed to providing solutions based on artificial intelligence and intelligent ophthalmic hardware in disease screening and diagnosis through cooperation with excellent ophthalmic medical teams.

At present, Zhiyuan Hui chart has developed diabetic retinopathy AI, eye health multi disease fundus image AI, glaucoma early screening AI three ophthalmic AI products. Among them, "diabetic retinopathy fundus image assistant diagnostic software" can be used to identify retinal complications of diabetic patients, and identify the fundus images and assist in the diagnosis of disease severity according to the level of disease in the region and the patients. Three types of NMPA medical devices and CE certification have been obtained.

Zhiyuan huitu's "multi disease fundus image aided diagnosis software" is the world's first multi disease fundus AI image product with EU CE certification and nmpa innovative medical devices. Not only that, it also took the lead in going international, cooperated with luneau technology, and took this opportunity to enter the vision centers and pharmacies in Germany, Italy, Spain and other countries, becoming the first domestic medical AI company to go to the EU market and realize commercialization.

Sun Yuhui, founder and CEO of Zhiyuan huitu, said: "Thank the top investment institutions for their recognition of Zhiyuan huitu. In the future, Zhiyuan huitu will focus on eye health, continuously enlarge its own advantages, deeply strengthen the research and development and academic research of ophthalmic AI products, use the genes of data intelligence technology in its own health field to expand the types of diseases, realize the combined application of multiple products, and carry out more work in the direction of chronic disease management. At the same time, Zhiyuan huitu will It will also broaden the business segment, develop auxiliary software systems and hardware facilities, adopt a comprehensive development strategy of software and hardware integration, lead and participate in the research and development of small portable and cost-effective ophthalmic imaging equipment more suitable for China's medical market, further expand the R & D and sales team, and accelerate the commercial implementation of products. "

For this round of follow-up investment, Liang Qiao, vice president of Danlu capital investment, an old shareholder, said: "With the industrialization of artificial intelligence medical diagnosis technology from laboratory, early screening and early diagnosis of diseases will usher in a revolutionary era of high efficiency and inclusive benefits. Zhiyuan huitu has the best medical AI team, rich product layout and excellent clinical data, and has established a significant competitive advantage. It has important clinical significance and health economics value for early detection and timely treatment of diseases "We are very pleased to invest in Zhiyuan huitu, a leading company in this field in China, and have given continuous support in multiple rounds of financing. We look forward to Zhiyuan huitu becoming a successful model for the efficient implementation of artificial intelligence in China in the future."

Source of information:

Zhiyuan huitu official website:

https://www.vistel.cn/

Arterial network, original link:

https://mp.weixin.qq.com/s/Y8Cmult1lTnx2BMXzoMopw